Soleno Therapeutics Stands With the Prader-Willi Syndrome Community
Soleno Therapeutics Stands With the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome community
5月15日是普拉德-威利综合症宣传日，与Soleno Therapeutics一起为Prader-Willi综合症社区分享希望和善良的信息
REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease.
加利福尼亚州雷德伍德城，2024年5月15日（GLOBE NEWSWIRE）——开发治疗罕见疾病的新疗法的临床阶段生物制药公司索理诺治疗公司（纳斯达克股票代码：SLNO）（“Soleno” 或 “公司”）今天启动了一项开创性的计划，以纪念普拉德-威利综合症（PWS）宣传日。该活动旨在提高人们对PWS的认识，并庆祝患有这种危及生命的疾病的人。
PWS is a rare and complex genetic disease affecting approximately one in every 15,000 births globally. Among its characteristics in infants are hypotonia (weak muscles), low muscle mass, and weak suck at birth. As the child develops, the hallmark symptom of potentially life-threatening hyperphagia (insatiable hunger) becomes evident, which can lead to early onset morbid obesity. Other characteristic features of PWS include significant behavioral problems, incomplete sexual development, growth hormone deficiency, and intellectual disability. There is elevated mortality in PWS at all ages.
PWS是一种罕见而复杂的遗传性疾病，全球每15,000例新生儿中约有一人受到影响。它在婴儿中的特征包括肌张力低下（肌肉无力）、肌肉质量低下和出生时吸吮力弱。随着孩子的发育，可能危及生命的食欲过度（贪得无厌的饥饿）的标志性症状变得显而易见，这可能导致病态肥胖的早期发作。PWS的其他特征包括严重的行为问题、性发育不完全、生长激素缺乏和智力障碍。所有年龄段的PWS的死亡率都很高。
Soleno's PWS Awareness Month campaign includes a vibrant billboard in New York Times Square featuring nearly 100 individuals from the PWS community, who, along with Soleno Therapeutics, invite others to learn more about PWS and share words of hope, encouragement, and kindness. Through a new website at , the company seeks to foster greater understanding and support for the PWS community.
索理诺的PWS宣传月活动包括纽约时代广场上一个充满活力的广告牌，其中包括来自PWS社区的近100名个人，他们与Soleno Therapeutics一起邀请其他人进一步了解PWS，分享希望、鼓励和善良的话语。通过一个新网站，网址为 ，该公司力求增进对PWS社区的理解和支持。
"At Soleno, we are deeply committed to making a meaningful difference in the lives of individuals with Prader-Willi syndrome," said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics. "This campaign aims to highlight the resilience and beauty within the PWS community, and we hope it will inspire greater awareness, understanding, and support for those living with this rare disease."
Soleno Therapeutics首席执行官阿尼什·巴特纳加尔博士表示：“在索理诺，我们坚定地致力于为普拉德-威利综合征患者的生活带来有意义的改变。”“该活动旨在突出PWS社区内部的韧性和美丽，我们希望它将激发对这种罕见疾病患者的更大认识、理解和支持。”
May is recognized as Prader-Willi Syndrome Awareness Month, supported annually by organizations such as the International Prader-Willi Syndrome Organization (IPWSO), the Foundation for Prader-Willi Research (FPWR) and the Prader-Willi Syndrome Association USA (PWSA USA), and many more organizations around the world. In the United States, May 15th has been designated National Prader-Willi Syndrome Awareness Day, thanks to a joint resolution by United States Congressman Paul D. Tonko (D-NY) and Congresswoman Maria Elvira Salazar (R-FL) in 2023.
五月被认定为普瑞德-威利综合症宣传月，每年都得到国际普拉德威利综合症组织（IPWSO）、普瑞德威利研究基金会（FPWR）和美国普拉德威利综合症协会（PWSA USA）等组织以及世界各地更多组织的支持。在美国，5月15日被定为全国普拉德-威利综合症宣传日，这要归功于美国国会议员保罗·唐科（D-NY）和国会女议员玛丽亚·埃尔维拉·萨拉查（R-FL）在2023年通过的一项联合决议。
To learn more about Soleno Therapeutics' commitment to the PWS community and how you can get involved in the campaign, visit .
要详细了解索理诺疗法对PWS社区的承诺以及如何参与该活动，请访问。
About Soleno Therapeutics, Inc.
关于 Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company's lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program to support a planned NDA submission.
Soleno专注于治疗罕见疾病的新疗法的开发和商业化。该公司的主要候选药物DCCR（二氮氧化胆碱）缓释片剂，一种用于治疗普拉德威利综合征（PWS）的每日一次的口服片剂，最近完成了其第三阶段开发计划，以支持计划提交的保密协议。
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
公司联系人：
布莱恩·里奇
LifeSci 顾问有限公司
212-915-2578
译文内容由第三方软件翻译。